Diabetes

= ILF Board Member Author(s)

 

Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With

Prediabetes and Diabetes

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American

Heart Association and the Heart Failure Society of America

Treatment patterns and associated factors in 14,668 people with type 2 diabetes initiating a second‐line therapy: results from the global DISCOVER study programme

Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline

Diabetes phenotypes: Beyond IDDM vs NIDDM

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

Eligibility of patients with type 2 diabetes for SGLT‐2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry

Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes

Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

Repositioning of Itraconazole for the Management of Ocular Neovascularization Through Surface-Modified Nanostructured Lipid Carriers.

Sugar Addiction: From Evolution to Revolution

Glucose-Mediated Glucose Disposal at Baseline Insulin Is Impaired in IFG

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.

Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus

More than A1C: Types of success among adults with type-2 diabetes participating in a technology-enabled nurse coaching intervention.

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial

Slides from Paul D. Rosenblit, MD, PhD, FACE, FNLA

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan.

Baseline and changes in serum uric acid independently predict glucose control among community-dwelling women.

Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).

Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia.

Full Article

Exenatide effects on gastric emptying and oral glucose appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.

Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose.

Vitamin C deficiency aggravates tumor necrosis factor α-induced insulin resistance.

Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study.

Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).

Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled on once daily basal insulin: a randomized, phase IV study.

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial.

Canakinumab for secondary prevention of atherosclerotic disease.

Pharmacological management of cystic fibrosis related diabetes.

Insulin-like growth factor binding protein-1 improves vascular endothelial repair in male mice in the setting of insulin resistance.

The proportion of familial cases of type 1 diabetes is increasing simultaneously with the disease incidence: Eighteen years of the Israeli Pediatric Diabetes Registry.

Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Datasets.